NEW YORK (GenomeWeb News) – Agilent Technologies and Molecular Discovery on Sunday announced a co-marketing agreement to provide an advanced metabolite identification platform to biopharmaceutical researchers.
Under the terms of the deal, Agilent's high-resolution liquid chromatography/mass spectrometry technology will be co-marketed with Molecular Discovery's Mass-MetaSite software "to enable superior identification and analysis of complex biological mixtures," the firms said in a joint statement.
Gus Salem, vice president and general manager of Agilent's Biological Systems Division, said that identifying and predicting human drug metabolism have been major obstacles in the drug-development process.
"Whereas traditional metabolite identification, synthesis and toxicity testing has been costly and time consuming for researchers, our combined industry-leading technologies will now give them faster, more accurate data, and the confidence they need to ensure the safety of their products much earlier in the preclinical phase of development," he said in a statement.
All therapeutic compounds are subject to preclinical metabolic toxicity testing before human clinical trials can begin as part of the US Food and Drug Administration new-drug application process. Metabolites are identified and evaluated for their effect on human metabolism, a process that can be expensive and time-consuming for drug manufacturers.
The deal between Agilent and Molecular Discovery, the partners said, will provide customers with a solution "that bridges the gap between sophisticated laboratory software and hardware capabilities. The analytical benefits of Agilent's high-resolution instruments, integrated with Molecular Discovery's robust predictive metabolite identification software tools, will advance drug research and discovery by enabling the decisive identification and conversion of large volumes of data into usable information."
Financial and other terms of the agreement were not disclosed.